P ercutaneous coronary intervention (PCI) for chronic total occlusion (CTO) is still challenging, and there are unmet needs even with the availability of drug-eluting stents (DESs). [1] [2] [3] [4] Despite the development of novel techniques and technologies for CTO intervention, the increased clinical and angiographic risk factors accompanying more complex procedures have been associated with worse clinical outcomes. [3] [4] [5] [6] The use of intravascular ultrasound (IVUS) has been recommended as 1 way to improve overall PCI clinical outcomes; however, few studies have evaluated its use during CTO intervention, and no randomized study has compared IVUS-guided CTO intervention with conventional angiography-guided intervention. [7] [8] [9] Background-There have been no randomized studies comparing intravascular ultrasound (IVUS)-guided versus conventional angiography-guided chronic total occlusion (CTO) intervention using new-generation drug-eluting stent Therefore, we conducted a prospective, randomized, multicenter trial designed to test the hypothesis that IVUS-guided CTO intervention is superior to angiography-guided intervention. Methods and Results-After successful guidewire crossing, 402 patients with CTOs were randomized to the IVUS-guided group (n=201) or the angiography-guided group (n=201) and secondarily randomized to Resolute zotarolimus-eluting stents or Nobori biolimus-eluting stents. The primary and secondary end points were cardiac death and a major adverse cardiac event defined as the composite of cardiac death, myocardial infarction, or target-vessel revascularization, respectively. After 12-month follow-up, the rate of cardiac death was not significantly different between the IVUSguided group (0%) and the angiography-guided group (1.0%; P by log-rank test=0.16). However, major adverse cardiac event rates were significantly lower in the IVUS-guided group than that in the angiography-guided group (2.6% versus 7.1%; P=0.035; hazard ratio, 0.35; 95% confidence interval, 0.13-0.97). Occurrence of the composite of cardiac death or myocardial infarction was significantly lower in the IVUS-guided group (0%) than in the angiography-guided group (2.0%; P=0.045). The rates of target-vessel revascularization were not significantly different between the 2 groups. In the comparison between Resolute zotarolimus-eluting stent and Nobori biolimus-eluting stent, major adverse cardiac event rates were not significantly different (4.0% versus 5.7%; P=0.45).
Therefore, we conducted a prospective, multicenter, randomized trial designed to test the hypothesis that IVUS-guided CTO intervention is superior to angiography-guided CTO intervention. We also compared 12-month clinical outcomes after the implantation of different new-generation DESs.
Methods

Study Population
This Chronic Total Occlusion InterVention with drUg-eluting Stents guided by IVUS (CTO-IVUS) study was a prospective, multicenter, randomized trial. After successful guidewire crossing of CTO lesions, patients with a CTO fulfilling study criteria were randomly assigned in a 1:1 ratio to IVUS or angiography guidance, and then randomly assigned again in a 1:1 ratio (2×2 design) to Endeavor Resolute Integrity zotarolimus-eluting stents (R-ZES; Medtronic Vascular Inc, Santa Rosa, CA) or Nobori biolimus-eluting stents (N-BES; Terumo Corporation, Tokyo, Japan). Patients with CTO who were aged 20 to 80 years and had typical symptomatic angina or positive test results for functional evaluation of ischemia were eligible for this study. Key exclusion criteria were as follows: (1) unprotected left main disease or in-stent restenosis; (2) presentation of acute coronary syndrome at CTO intervention; (3) left ventricle ejection fraction <30%; and (4) IVUS use before randomization. The institutional review boards at each center approved this study. All enrolled patients received a detailed explanation on this study including the processes of study and potential complications of CTO procedures, and then provided the written informed consent form before randomization.
Procedure and Randomization
Using an interactive web-based response system, study participants were randomly assigned and stratified by participating center. In patients assigned to the IVUS-guided group, it is strongly recommended to follow the below criteria: (1) minimal stent area ≥distal reference lumen area; (2) stent area at CTO segment ≥5 mm 2 as far as vessel area permits; and (3) complete stent apposition. IVUS devices, pullback methods, use at poststenting and prestenting, and numbers of exams were all left to the discretion of physicians. After PCI, dual antiplatelet therapy with aspirin (100 mg) and clopidogrel (75 mg) QD was used for at least 12 months. In the absence of contraindications, the use of statins and β-blockers was strongly recommended.
End Points, Definition, and Follow-Up
The prespecified primary end point was the occurrence of cardiac death. The secondary end point was the major adverse cardiac event (MACE) defined as the composite of cardiac death, myocardial infarction (MI), or target-vessel revascularization at 12 months. All deaths were considered cardiac death unless an unequivocal noncardiac cause could be established. 10, 11 MI was defined as the presence of clinical symptoms, electrocardiographic changes, or abnormal imaging findings associated with MI combined with an increase in creatine kinase-MB above the upper normal limit or troponin T/I greater than the 99th percentile of the upper normal limit, unrelated to an interventional procedure. 10, 11 Stent thrombosis was defined as definite or probable stent thrombosis according to the Academic Research Consortium. 10 Target-vessel revascularization was defined as repeat
WHAT IS KNOWN
• The use of intravascular ultrasound has been recommended for the improvement of clinical outcomes after coronary intervention.
• However, no randomized study has compared intravascular ultrasound-guided chronic total occlusion intervention with conventional angiography-guided intervention using new-generation drug-eluting stent.
WHAT THE STUDY ADDS
• This Chronic Total Occlusion InterVention with drUg-eluting Stents (CTO-IVUS) study, the first randomized trial, demonstrated that intravascular ultrasound-guided percutaneous coronary intervention may improve 12-month major adverse cardiac event rates after drug-eluting stent implantation when compared with conventional angiography-guided chronic total occlusion intervention.
• Two new-generation drug-eluting stents (Resolute zotarolimus-eluting stent and Nobori biolimuseluting stent) showed comparable 12-month clinical outcomes after chronic total occlusion intervention. PCI or bypass surgery of the target vessel with ischemic symptoms or positive stress test results as well as lesion severity of >50% angiographic diameter stenosis by quantitative angiographic analysis (QCA). 10 Procedure success was defined as a final thrombolysis in MI flow grade ≥2 without death or fatal complication during the procedure requiring emergent operation. Device success was defined as residual stenosis ≤30% by visual assessment after successful stent implantation. Congestive heart failure was defined as left ventricular ejection fraction ≤40% or dyspnea with congestion on radiograph. All data were collected using a web-based system, and clinical follow-up was performed at 1, 3, 9, and 12 months after the index procedure either by clinic visit or by telephone contact. All clinical events were independently monitored and assessed by a clinical event committee blinded to randomization. Detailed explanations on participating institutes, total inclusion and exclusion criteria, procedures, QCA, and IVUS analysis are supplied in the Data Supplement.
Statistics
Given that no comparative data had been published on IVUS guidance versus angiography guidance for CTO intervention in the DES era, a power calculation for sample size was performed with the following assumptions: (1) the event rate of CTO would be similar to that of diffuse long lesions and (2) current DESs could reduce the target-vessel revascularization rate >50%. A prior randomized trial evaluating bare-metal stent implantation for the treatment of diffuse long lesions reported that the composite rate of cardiac death, MI, or target-lesion revascularization was 12% for IVUS-guided intervention and 27% for angiography-guided intervention. 12 Therefore, we assumed that the difference in the occurrence of MACE would be ≈8% (4% in the IVUS-guided group and 12% in the angiographyguided group). Assuming a dropout rate of 10%, enrolling 400 patients was found to be sufficient to demonstrate the superiority of IVUS-guided PCI for CTO, with 80% power to detect a difference and a 2-sided α error rate of 0.05. The comparison between R-ZES versus N-BES was performed in an exploratory manner.
All data were expressed as number and percentage or mean±SD. Continuous variables were compared by independent t tests, and categorical variables were compared by χ 2 test or Fisher exact test. The cumulative event rates were calculated using the Kaplan-Meier method and compared using log-rank test. Univariate Cox proportional hazard model was used to calculated hazard ratios. The intention-to-treat principle was used in all analyses. A 2-sided P<0.05 was considered significant. Analyses were performed using SPSS version 20 (Chicago, IL) and R version 2.10 (R Development Core Team, Vienna, Austria).
Results
Baseline Characteristics
Patient enrollment and study design are shown in Figure 1 . Between March 2012 and August 2013, a total of 467 patients were screened from 20 centers and 402 patients in total (each with a single CTO) were finally enrolled and randomized to treatment after successful guidewire-crossing of the CTO lesion.
The groups (IVUS versus angiography) were well matched for baseline clinical and angiographic characteristics without significant differences (Table 1) . However, high-pressure poststent balloon dilation was more frequently performed with a greater maximal poststent balloon pressure in the IVUS-guided group than the angiography-guided group (51.2% versus 41.3%; P=0.045). On QCA, postprocedural minimum lumen diameter (MLD) was significantly greater in the IVUS-guided group than in the angiography-guided group (2.64±0.35 versus 2.56±0.41 mm; P=0.025). There were no complications related with IVUS evaluation. Postprocedural IVUS analysis in the IVUS-guided group is provided in Table  I In the comparison between R-ZES and N-BES, there was no significant difference of baseline clinical, angiographic, and procedural characteristics including QCA (Table 2) .
Clinical Outcomes
Mean follow-up duration was 359±34 days in the IVUSguided group and 359±37 days in the angiography-guided group (P=0.907); 200 patients of IVUS-guided group (99.5%) and 201 patients (100%) in the angiography-guided group finished 12-month clinical follow-up. During 12-month followup, cardiac death did not occur in the IVUS-guided group but occurred in 2 patients of the angiography-guided group without statistical significance (0% versus 1.0%; P by the log-rank test=0.16). The occurrence of MACE was significantly lower in the IVUS-guided group than in the angiography-guided group (2.6% versus 7.1%; P by the log-rank test=0.035; hazard ratio, 0.35; 95% confidence interval, 0.13-0.97; Table 3 ; Figure 2A ). The occurrence of the composite of cardiac death or MI was also lower in the IVUS-guided group than in the angiography-guided group but the significance was marginal (0% versus 2.0%; P by the log-rank test=0.045; Table 3 ; Figure 2B) . Cardiac death or MI occurred in 4 patients of the angiography-guided group, not in the IVUS-guided group and pre-and postprocedural angiographic findings of these patients are provided in Figure 3 (detailed explanation is provided in Table II in the Data Supplement). As for individual components of MACE, target-vessel revascularization rates were not significantly different between 2 groups (2.6% versus 5.2%; P by the log-rank test=0.19; Table 3 ; Figure 2C ). Other components of MACE did not differ between the groups. There were no significant differences in the analyses of periprocedural cardiac enzyme increases between the groups (Table 3) .
When comparing 2 types of DESs, we did not detect a significant difference in the occurrence of MACE or other individual components between R-ZES and N-BES (Table 4 ; Figure 4 ).
Discussion
To the best of our knowledge, this CTO-IVUS study is the first randomized trial investigating the clinical benefits of IVUS guidance for CTO intervention after successful guidewire crossing, especially in the new-generation DES era. This study demonstrated that IVUS-guided PCI may improve clinical outcomes after DES implantation when compared with conventional angiography-guided CTO intervention, In addition, 2 new-generation DESs (R-ZES and N-BES) showed comparable 12-month clinical outcomes after CTO intervention. Previous studies have reported that IVUS is a valuable tool for recanalization of the CTO under specific situations. 13, 14 However, there are concerns on device-related complications and prolonged procedure times when using IVUS. In addition, there is little data on the relationship between successful CTO recanalization using IVUS guidance and clinical outcomes after stent implantation. IVUS use after successful guidewire crossing is helpful in selecting stent size and length, ensuring lesion coverage and stent optimization and detecting procedure-related complications, all of which could contribute to better clinical outcomes. 7, 9, [15] [16] [17] Recently, we reported the clinical usefulness of IVUS-guided CTO intervention with DESs (n=534), with both crude and propensity score-matching analyses showing that IVUS-guided CTO intervention was associated with improved 2-year clinical outcomes, especially stent thrombosis and MI. 18 However, because this was a retrospective study, we conducted the current multicenter, prospective, randomized study to further evaluate the effect of IVUS guidance for CTO intervention on clinical outcomes after new-generation DES implantation.
In the present study, we found that IVUS-guided CTO intervention was associated with a significantly lower MACE rate during the 12-month follow-up. These improved outcomes for the IVUS-guided group could not be explained by a single predominant factor. High-pressure ballooning was not frequently performed in both groups and there was no significant difference in the size and length of the implanted stents in this study. However, high-pressure poststent ballooning was more frequently performed in the IVUS-guided group even with minimal difference between the groups and could cause a larger postprocedural MLD, one of the main factors for the prevention of restenosis and stent thrombosis. 1, 12 These features were also noted in other IVUS studies targeting diffuse long lesions. These studies suggest that a larger postprocedural MLD is one of the main contributing factors to the improved outcome and a similar relation could be expected in CTO requiring multiple stents. 9, 12, 18 However, because some studies failed to demonstrate the superiority of IVUS-guided PCI even with a greater postprocedural MLD or a higher frequency of high-pressure ballooning and the difference of postprocedural MLD in this study was minimal, a future study investigating other contributing factors to the improved clinical outcome of the IVUS-guided CTO intervention will be needed. 19, 20 The impact of modest difference of MLD or pressure after poststent ballooning on the real clinical outcome should also be investigated. 19, 20 Although IVUS-guided CTO intervention did not reduce cardiac mortality in the current study, other major results are consistent with 4 meta-analyses of IVUS-guided versus angiographic-guided DES implantation (the most recent involved 3 randomized trials and 14 observational studies with 26 503 patients), which found that IVUS guidance reduced stent thrombosis, MI, repeat revascularization, and mortality despite using more stents and longer stents. 17, [21] [22] [23] A propensity score-matched analysis was possible in 9 studies and revealed no evidence of heterogeneity or publication bias. 17, 21 Although 2 new-generation DESs used in this study, R-ZES and N-BES, have their own unique features such as specific diffused drugs (zotarolimus versus biolimus), different polymer types (durable versus degradable), or stent designs (thin-versus thick-strut thickness) and have shown the improved and comparable clinical outcomes by balancing efficacy and safety, there are minimal data for these DESs in the field of CTO. [24] [25] [26] In this CTO-IVUS study, R-ZES and N-BES were randomly used and produced favorable clinical outcomes without significant differences between the 2 DESs. Similar to the results of recent randomized study comparing ZES with BES, 2 DESs for current CTO study showed a relatively low rate of stent thrombosis at 12 months even in the more complex lesions, CTO. 26 However, as the primary goal of this study was not to compare these DESs and statistical power for the noninferiority between 2 DESs would be underpowered, these should be taken into account when interpreting and applying the results. In addition, a more long-term evaluation including late DES complications will be needed for the assessment of the occurrence of late complications after DES implantation in CTO. 
Limitations
A few of our hypotheses for power calculation were arbitrary because of the lack of published studies that compare IVUS and angiography guidance for DES implantation in CTO lesions. Overall, this study showed low event rates, especially for cardiac death and MI, and small differences in clinical outcomes with marginal statistical significances. These could cause the concerns on statistical power and need for the application of different statistical methods. For the comparison of acute procedure outcomes, only QCA was available; however, postprocedural QCA may not have been sensitive enough to detect differences between the 2 groups. In the IVUS-guided group, there are no standardized methods for IVUS evaluation or management guideline according to the procedural steps and no detailed data on the additional therapeutic actions according to the IVUS findings. In addition, the particular effects of IVUS-based therapeutic measures were not assessed, as serial IVUS recordings were not systematically collected. IVUS criteria proposed in this study may have been too conservative. These factors may have reduced the impact on clinical outcomes. Especially, as compared with the Multicenter Ultrasound Stenting in Coronaries (MUSIC) study, minimum stent area of this study was too small. 27 However, MUSIC study was conducted in the bare-metal stents era targeting the relatively short-length lesions and the controversies on the clinical outcomes according to the degree of stent expansion exist in the current DES era. 27, 28 In prior randomized IVUS study targeting diffuse long lesions, minimum stent area was similar to that of CTO-IVUS study (5.0-5.2 mm 2 ). 9 A future study would be needed for the definite role and cutoff value for optimal stent expansion in CTO intervention using DESs. Our analyses did not identify a definite reason for the improved clinical outcomes in the IVUS-guided group; we only speculate that a larger postprocedural MLD contributes Data are presented as n (% of the cumulative events). P values are from the log-rank test. CI indicates confidence interval; MACE, major adverse cardiac events; and MI, myocardial infarction. to the improved outcomes. Finally, the follow-up duration was only 12 months, and there were no data on follow-up angiographic findings including restenosis patterns and changes in ischemia or the changes of cardiovascular medication after CTO intervention. A longer term follow-up will be needed for the investigation of fatal complications such as death or MI.
Conclusions
Although IVUS guidance for CTO intervention did not significantly reduce cardiac mortality, IVUS-guided CTO intervention did significantly improve MACE rate during the 12 months after DES implantation when compared with conventional angiography-guided CTO intervention. In addition, the new-generation DESs, R-ZES and N-BES, showed similar clinical results after CTO intervention.
Sources of Funding
This study was supported by a grant from the Cardiovascular Research Center, Seoul, Korea.
Disclosures
None.
